» Articles » PMID: 37093405

Monoclonal Antibodies for COVID-19 in X-linked Agammaglobulinemia: a Case Series

Overview
Journal J Clin Immunol
Publisher Springer
Date 2023 Apr 24
PMID 37093405
Authors
Affiliations
Soon will be listed here.
Citing Articles

Case report: Rapidly progressive neurocognitive disorder with a fatal outcome in a patient with PU.1 mutated agammaglobulinemia.

Miskovic R, Ljubicic J, Bonaci-Nikolic B, Petkovic A, Markovic V, Rankovic I Front Immunol. 2024; 15:1324679.

PMID: 38500873 PMC: 10945545. DOI: 10.3389/fimmu.2024.1324679.

References
1.
Soresina A, Moratto D, Chiarini M, Paolillo C, Baresi G, Foca E . Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol. 2020; 31(5):565-569. PMC: 7264678. DOI: 10.1111/pai.13263. View

2.
Devassikutty F, Jain A, Edavazhippurath A, Joseph M, Peedikayil M, Scaria V . X-Linked Agammaglobulinemia and COVID-19: Two Case Reports and Review of Literature. Pediatr Allergy Immunol Pulmonol. 2021; 34(3):115-118. PMC: 8664121. DOI: 10.1089/ped.2021.0002. View

3.
Squire J, Joshi A . Response to mRNA COVID-19 vaccination in three XLA patients. Vaccine. 2022; 40(36):5299-5301. PMC: 9345887. DOI: 10.1016/j.vaccine.2022.07.046. View

4.
Lindahl H, Klingstrom J, Da Silva Rodrigues R, Christ W, Chen P, Ljunggren H . Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant. J Clin Immunol. 2022; 42(6):1130-1136. PMC: 9090539. DOI: 10.1007/s10875-022-01283-9. View

5.
Yamasoba D, Kosugi Y, Kimura I, Fujita S, Uriu K, Ito J . Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis. 2022; 22(7):942-943. PMC: 9179126. DOI: 10.1016/S1473-3099(22)00365-6. View